Reversible Decrease of Portal Venous Flow in Cirrhotic Patients: A Positive Side Effect of Sorafenib

Portal hypertension, the most important complication with cirrhosis of the liver, is a serious disease. Sorafenib, a tyrosine kinase inhibitor is validated in advanced hepatocellular carcinoma. Because angiogenesis is a pathological hallmark of portal hypertension, the goal of our study was to deter...

Descripción completa

Detalles Bibliográficos
Autores principales: Coriat, Romain, Gouya, Hervé, Mir, Olivier, Ropert, Stanislas, Vignaux, Olivier, Chaussade, Stanislas, Sogni, Philippe, Pol, Stanislas, Blanchet, Benoit, Legmann, Paul, Goldwasser, François
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3038868/
https://www.ncbi.nlm.nih.gov/pubmed/21340026
http://dx.doi.org/10.1371/journal.pone.0016978

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3038868/
https://www.ncbi.nlm.nih.gov/pubmed/21340026
http://dx.doi.org/10.1371/journal.pone.0016978

Ejemplares similares